Bonyf NV
bonyf N.V. engages in the research, development, production, and distribution of oral and dental products in Belgium and internationally. The company offers PerioTabs, a brushing solution for gums, teeth, and dental implants to help reduce gingivitis, periodontitis, peri-mucositis, and peri-implantitis; and AphtoFix, a film-forming cream for the local treatment of mouth ulcers. It also provides d… Read more
Bonyf NV (MLBON) - Net Assets
Latest net assets as of September 2021: €433.97K EUR
Based on the latest financial reports, Bonyf NV (MLBON) has net assets worth €433.97K EUR as of September 2021.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€1.68 Million) and total liabilities (€1.25 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €433.97K |
| % of Total Assets | 25.82% |
| Annual Growth Rate | 50.21% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 539.79 |
Bonyf NV - Net Assets Trend (2019–2024)
This chart illustrates how Bonyf NV's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Bonyf NV (2019–2024)
The table below shows the annual net assets of Bonyf NV from 2019 to 2024.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | €2.64 Million | -1.36% |
| 2023-12-31 | €2.68 Million | -28.04% |
| 2022-12-31 | €3.73 Million | +1230.28% |
| 2020-12-31 | €280.06K | -18.93% |
| 2019-12-31 | €345.47K | -- |
Equity Component Analysis
This analysis shows how different components contribute to Bonyf NV's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 8015.1% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | €7.06 Million | 267.10% |
| Other Components | €7.34K | 0.28% |
| Total Equity | €2.64 Million | 100.00% |
Bonyf NV Competitors by Market Cap
The table below lists competitors of Bonyf NV ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Won Tech Co. Ltd.
KO:336570
|
$43.36K |
|
Notable Labs Inc.
NASDAQ:NTBL
|
$43.38K |
|
LIBERTY INT QVC-A (LB3A.SG)
STU:LB3A
|
$43.40K |
|
Ashtead Technology Holdings PLC
LSE:AT
|
$43.41K |
|
SUPERIOR PLUS
BE:8SP
|
$43.32K |
|
DAH SING FIN HLDGS
MU:DSR
|
$43.31K |
|
Bridge Solutions Hub S.A.
WAR:BSH
|
$43.28K |
|
TEMPLE BAR INV.TR. LS-05
F:1N00
|
$43.27K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Bonyf NV's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 2,680,922 to 2,644,412, a change of -36,510 (-1.4%).
- Net loss of 36,509 reduced equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-36.51K | -1.38% |
| Other Changes | €-1.00 | -0.0% |
| Total Change | €- | -1.36% |
Book Value vs Market Value Analysis
This analysis compares Bonyf NV's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.00x
- The company is trading below its book value, potentially indicating the market believes the assets are overvalued on the balance sheet or anticipates future losses.
- The price-to-book ratio has decreased from 7.63x to 1.00x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | €0.59 | €4.48 | x |
| 2020-12-31 | €0.48 | €4.48 | x |
| 2022-12-31 | €6.33 | €4.48 | x |
| 2023-12-31 | €4.55 | €4.48 | x |
| 2024-12-31 | €4.49 | €4.48 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Bonyf NV utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -1.38%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -12.97%
- • Asset Turnover: 0.08x
- • Equity Multiplier: 1.26x
- Recent ROE (-1.38%) is above the historical average (-19.85%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | 55.19% | 5.96% | 2.31x | 4.01x | €156.13K |
| 2020 | -25.06% | -2.96% | 1.72x | 4.93x | €-98.18K |
| 2022 | -89.06% | -1196.14% | 0.07x | 1.12x | €-3.69 Million |
| 2023 | -38.97% | -337.68% | 0.10x | 1.15x | €-1.31 Million |
| 2024 | -1.38% | -12.97% | 0.08x | 1.26x | €-300.95K |
Industry Comparison
This section compares Bonyf NV's net assets metrics with peer companies in the Medical Instruments & Supplies industry.
Industry Context
- Industry: Medical Instruments & Supplies
- Average net assets among peers: $692,194,668
- Average return on equity (ROE) among peers: -400.27%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Bonyf NV (MLBON) | €433.97K | 55.19% | 2.87x | $43.34K |
| Crossject (ALCJ) | $1.65 Million | -647.41% | 11.18x | $105.49 Million |
| I.Ceram SA (ALICR) | $2.61 Million | -58.47% | 1.19x | $95.27K |
| Safe Orthopaedics SA (ALSAF) | $398.00K | -1685.68% | 36.39x | $139.52K |
| Spineway (ALSPW) | $22.01 Million | -14.25% | 0.26x | $6.68 Million |
| Amplitude Surgical SAS (AMPLI) | $85.50 Million | -10.51% | 2.27x | $14.07 Million |
| EssilorLuxottica S. A. (EL) | $4.04 Billion | 14.67% | 0.88x | $61.18 Billion |